MX2020009900A - Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal. - Google Patents

Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal.

Info

Publication number
MX2020009900A
MX2020009900A MX2020009900A MX2020009900A MX2020009900A MX 2020009900 A MX2020009900 A MX 2020009900A MX 2020009900 A MX2020009900 A MX 2020009900A MX 2020009900 A MX2020009900 A MX 2020009900A MX 2020009900 A MX2020009900 A MX 2020009900A
Authority
MX
Mexico
Prior art keywords
specific
gastrointestinal tract
methods
melanocortin receptor
peptide formulations
Prior art date
Application number
MX2020009900A
Other languages
English (en)
Inventor
Stephen Kwaku Dordunoo
John Harold Dodd
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of MX2020009900A publication Critical patent/MX2020009900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formulaciones, composiciones y metodos para el suministro de peptidos especificos para el receptor de melanocortinas, particularmente peptidos ciclicos selectivos y especificos para el receptor de melanocortinas 1, a la luz del tubo gastrointestinal para el tratamiento de enfermedades, indicaciones, afecciones y sindromes del tubo gastrointestinal mediados por el receptor de melanocortinas o sensibles a este.
MX2020009900A 2018-03-23 2019-03-22 Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal. MX2020009900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647000P 2018-03-23 2018-03-23
PCT/US2019/023575 WO2019183472A1 (en) 2018-03-23 2019-03-22 Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery

Publications (1)

Publication Number Publication Date
MX2020009900A true MX2020009900A (es) 2021-01-08

Family

ID=67988087

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009900A MX2020009900A (es) 2018-03-23 2019-03-22 Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal.

Country Status (13)

Country Link
US (1) US20220088146A1 (es)
EP (1) EP3768245A4 (es)
JP (1) JP2021523931A (es)
KR (1) KR20210003759A (es)
CN (1) CN112188888A (es)
AU (1) AU2019239300A1 (es)
BR (1) BR112020019128A2 (es)
CA (1) CA3095036A1 (es)
EA (1) EA202092275A1 (es)
IL (1) IL277496A (es)
MX (1) MX2020009900A (es)
PH (1) PH12020551596A1 (es)
WO (1) WO2019183472A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022009398A (es) * 2020-02-03 2022-11-07 Palatin Technologies Inc Péptidos cíclicos específicos de receptores unidos a diamina.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
FR2937868B1 (fr) * 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
WO2010144341A2 (en) * 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
WO2010144344A2 (en) * 2009-06-08 2010-12-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
MX2012005862A (es) * 2009-11-23 2012-09-07 Palatin Technologies Inc Peptidos ciclicos especificos del receptor de melanocortina-1.
TWI527809B (zh) * 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物
ES2718655T3 (es) * 2011-06-14 2019-07-03 Ipsen Pharma Sas Composición de liberación sostenida que contiene péptidos como ingrediente activo
JOP20200144A1 (ar) * 2012-04-30 2017-06-16 Tillotts Pharma Ag تركيبة عقار ذو إطلاق متأخر
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
US10588864B2 (en) * 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery

Also Published As

Publication number Publication date
EP3768245A4 (en) 2023-10-18
CA3095036A1 (en) 2019-09-26
US20220088146A1 (en) 2022-03-24
CN112188888A (zh) 2021-01-05
EP3768245A1 (en) 2021-01-27
AU2019239300A1 (en) 2020-11-19
IL277496A (en) 2020-11-30
JP2021523931A (ja) 2021-09-09
BR112020019128A2 (pt) 2021-01-12
PH12020551596A1 (en) 2021-08-16
WO2019183472A1 (en) 2019-09-26
EA202092275A1 (ru) 2021-02-09
KR20210003759A (ko) 2021-01-12

Similar Documents

Publication Publication Date Title
NZ761434A (en) Cytokine conjugates for the treatment of autoimmune diseases
PH12020551742A1 (en) Gip derivatives and uses thereof
MX2021005092A (es) Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MX2020010157A (es) Sistemas y metodo para suministro de gas terapeutico a pacientes en necesidad del mismo usando la medicion de flujo de gas de circuito de respiracion (bcg) mejorada.
MX356295B (es) Análogos de péptido de la hormona de estimulación de alfa-melanocito.
MY187047A (en) Selective pyy compounds and uses thereof
MX2019002998A (es) Celulas t con resistencia incrementada a la inmunosupresion.
EA201390194A1 (ru) Улучшенный рекомбинантный фолликул-стимулирующий гормон человека
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
EP3638298A4 (en) PEPTIDIC IMMUNOGENS FROM THE C-TERMINAL END OF A PROTEIN, ALPHA-SYNUCLEIN, AND COMPOSITIONS CONTAINING IT FOR THE TREATMENT OF SYNUCLEINOPATHIES
CL2015002620A1 (es) Derivados piridin-4-ilo
PH12019550241A1 (en) Mic-1 compounds and uses thereof
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2021015160A (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
PH12020551596A1 (en) Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery
MX2023008839A (es) Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.
MX2021004924A (es) Administracion oral de celulas terapeuticas de mamiferos.
MX2022009398A (es) Péptidos cíclicos específicos de receptores unidos a diamina.
MX2022003047A (es) Receptores de reconocimiento de antígenos dirigidos a cd371 y usos de los mismos.
MX2020001928A (es) Proceso para la preparacion de tubulisinas e intermediarios de las mismas.
WO2017078761A3 (en) Her-2-specific cyclized supr peptides